Humoral responses, particularly IgG1, to tumor antigens are associated with clinical outcomes in patients treated with immune checkpoint blockade. Plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies targeting citrullinated proteins.
Related products
| Catalog No. | Product Name | Description | Target |
|---|---|---|---|
| HY328026 | Anti-Human IL-6 Reference Antibody (Ziltivekimab | Research Grade Ziltivekimab (HY328026) is a humanized monoclonal antibody detecting Hybridoma growth factor in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications. | B-cell stimulatory factor 2, BSF-2, CDF, CTL differentiation factor, Hybridoma growth factor, IFN-beta-2, IFNB2, IL-6, IL6, Interferon beta-2, Interleukin-6 |
Quick access
Contact Us
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский